Logo image of GRCE

GRACE THERAPEUTICS INC (GRCE) Stock Fundamental Analysis

USA - NASDAQ:GRCE - US00439U1043 - Common Stock

3.19 USD
+0.05 (+1.59%)
Last: 11/21/2025, 4:30:01 PM
Fundamental Rating

3

GRCE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While GRCE has a great health rating, there are worries on its profitability. GRCE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GRCE has reported negative net income.
In the past year GRCE has reported a negative cash flow from operations.
GRCE had negative earnings in each of the past 5 years.
GRCE had a negative operating cash flow in each of the past 5 years.
GRCE Yearly Net Income VS EBIT VS OCF VS FCFGRCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

GRCE has a better Return On Assets (-13.29%) than 63.02% of its industry peers.
The Return On Equity of GRCE (-14.36%) is better than 69.79% of its industry peers.
Industry RankSector Rank
ROA -13.29%
ROE -14.36%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRCE Yearly ROA, ROE, ROICGRCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

GRCE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRCE Yearly Profit, Operating, Gross MarginsGRCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

GRCE has more shares outstanding than it did 1 year ago.
GRCE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GRCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRCE Yearly Shares OutstandingGRCE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
GRCE Yearly Total Debt VS Total AssetsGRCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

GRCE has an Altman-Z score of 0.13. This is a bad value and indicates that GRCE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GRCE (0.13) is comparable to the rest of the industry.
There is no outstanding debt for GRCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.13
ROIC/WACCN/A
WACCN/A
GRCE Yearly LT Debt VS Equity VS FCFGRCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 11.77 indicates that GRCE has no problem at all paying its short term obligations.
GRCE's Current ratio of 11.77 is amongst the best of the industry. GRCE outperforms 82.29% of its industry peers.
GRCE has a Quick Ratio of 11.77. This indicates that GRCE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 11.77, GRCE belongs to the best of the industry, outperforming 82.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.77
Quick Ratio 11.77
GRCE Yearly Current Assets VS Current LiabilitesGRCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.17% over the past year.
EPS 1Y (TTM)60.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GRCE will show a very strong growth in Earnings Per Share. The EPS will grow by 39.09% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-22.52%
EPS Next 2Y-5.73%
EPS Next 3Y38.69%
EPS Next 5Y39.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRCE Yearly Revenue VS EstimatesGRCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
GRCE Yearly EPS VS EstimatesGRCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GRCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRCE Price Earnings VS Forward Price EarningsGRCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRCE Per share dataGRCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as GRCE's earnings are expected to grow with 38.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.73%
EPS Next 3Y38.69%

More info and screens

0

5. Dividend

5.1 Amount

GRCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRACE THERAPEUTICS INC

NASDAQ:GRCE (11/21/2025, 4:30:01 PM)

3.19

+0.05 (+1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)02-13 2026-02-13
Inst Owners21.57%
Inst Owner ChangeN/A
Ins Owners3.59%
Ins Owner ChangeN/A
Market Cap44.12M
Revenue(TTM)N/A
Net Income(TTM)-9.57M
Analysts82.5
Price Target11.9 (273.04%)
Short Float %0.25%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.17%
Min EPS beat(2)40.72%
Max EPS beat(2)131.63%
EPS beat(4)3
Avg EPS beat(4)48.68%
Min EPS beat(4)-6.07%
Max EPS beat(4)131.63%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 2.54
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS4.82
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.29%
ROE -14.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.77
Quick Ratio 11.77
Altman-Z 0.13
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)72.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.81%
EPS Next Y-22.52%
EPS Next 2Y-5.73%
EPS Next 3Y38.69%
EPS Next 5Y39.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.85%
OCF growth 3YN/A
OCF growth 5YN/A

GRACE THERAPEUTICS INC / GRCE FAQ

What is the fundamental rating for GRCE stock?

ChartMill assigns a fundamental rating of 3 / 10 to GRCE.


Can you provide the valuation status for GRACE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to GRACE THERAPEUTICS INC (GRCE). This can be considered as Overvalued.


How profitable is GRACE THERAPEUTICS INC (GRCE) stock?

GRACE THERAPEUTICS INC (GRCE) has a profitability rating of 1 / 10.


What is the financial health of GRACE THERAPEUTICS INC (GRCE) stock?

The financial health rating of GRACE THERAPEUTICS INC (GRCE) is 7 / 10.


What is the earnings growth outlook for GRACE THERAPEUTICS INC?

The Earnings per Share (EPS) of GRACE THERAPEUTICS INC (GRCE) is expected to decline by -22.52% in the next year.